慢性自发性疹缓解定义和治疗退出:世界过敏组织的立场论文
Jorge Sánchez1, Helena Pite2, René Maximiliano Gómez3
1Group of Clinical and Experimental Allergy, Alma Mater de Antioquia Hospital, University of Antioquia, Medellín, Colombia.
The Journal of allergy and clinical immunology
|December 28, 2024
概括
一个共识定义慢性自发性疹 (CSU) 缓解为没有迹象或症状六个月没有药物治疗. 这种定义有助于标准化CSU缓解标准,并指导治疗调整.
科学领域:
- 过敏和免疫学 过敏和免疫学
- 皮肤病学 皮肤病学
- 临床医学 临床医学
背景情况:
- 在定义慢性自发性疹 (CSU) 缓解方面缺乏全球共识.
- 标准化定义对于一致的临床评估和研究至关重要.
研究的目的:
- 在慢性自发性疹症 (CSU) 中建立临床缓解的共识定义.
- 在CSU管理中制定治疗性降级的指导方针.
主要方法:
- 世界过敏组织疹委员会对纵向研究的系统审查.
- 关于CSU减免的定义的共识协议.
- 开发一个治疗降级方案.
主要成果:
- CSU缓解被定义为在没有药物治疗的情况下缺乏疹症的迹象/症状.
- 没有确立缓解开始的具体时间框架,但6个月缓解显示出与12个月缓解相似的复发率.
- 目前,CSU中没有炎症或机械性缓解的生物标志物.
结论:
- 世界过敏组织疹委员会建议将CSU临床缓解定义为至少6个月的无药物治疗的症状缓解.
- 需要进一步的研究来验证这一拟议定义的临床影响.
相关概念视频
Drugs Used in Lower Respiratory Disorders: Overview
349
Lower respiratory tract disorders present challenges that often require skilled and nuanced approaches for effective management. Common ailments, such as asthma and chronic obstructive pulmonary disease (COPD), have prompted the development of intricate treatment strategies involving bronchodilators and anti-inflammatory drugs, each tailored to ease breathing and revitalize the lungs.
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
349
Hypersensitivities
504
Hypersensitivity, also known as a hypersensitivity reaction or allergic reaction, is a condition where the body's immune system reacts abnormally to a foreign substance. Such substances, that cause hypersensitivity are referred to as an allergen, could be something typically harmless to most people, like pollen or certain foods.
Types of Hypersensitivities
Hypersensitivity reactions are categorized into four types: Type 1, Type 2, Type 3, and Type 4. Each type has a distinct mechanism...
Types of Hypersensitivities
Hypersensitivity reactions are categorized into four types: Type 1, Type 2, Type 3, and Type 4. Each type has a distinct mechanism...
504
Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
236
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
236
Antiasthma Drugs: Leukotriene Modifiers
241
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Leukotriene modifiers work through two distinct mechanisms:
241
Desensitization and Tachyphylaxis
1.5K
Tachyphylaxis is described as a rapid decrease in response to a drug after repeated or continuous administration of the same drug dose. It is a phenomenon where the body becomes less responsive to a particular substance or intervention over time, requiring higher doses or stronger interventions to achieve the same effect. It results from adaptive changes in the body's receptors, signaling pathways, or physiological processes that occur in response to prolonged exposure to a stimulus.
1.5K
Myasthenia Gravis: Overview and Treatment
1.2K
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
1.2K


